Board
Screen
Heat
Cal
Watch
News
Blog
TV
Home
/
UTHR
Home
/
UTHR

NASDAQ
$607.79
$607.79

Overview

Price performance
Low
$578.28
High
$609.20
Market open. Last updated: Nov 4, 2026, 6:12 PM UTC
$
607.79
6.47 (1.08%)
Average, 50 days
$530.53
$532.84
Open
$585.00
Previous close
$601.32
52-week high
$609.99
Oct 30, 2026 (6 days ago)
52-week low
$432.53
Nov 5, 2025 (13 months ago)
40.52%

Valuation & Estimates

Earnings

Financials

Insider Trading

Peer Analysis

Insights & Activity

Market Cap
26.07B
Volume
456 086
Total Return (3M)
17.09%
Total Return (1Y)
38.87%
11.08
Sector
Healthcare
Links
Tags
Healthcare
Biotechnology
NASDAQ
US
Website
unither.com
About
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

Frequently asked questions

UTHR · United Therapeutics Corporation

01What is United Therapeutics Corporation stock price today?

The current price of UTHR is $607.79 — it has increased by 1.08% since the previous close. Data as of Nov 4, 2026.

02Is United Therapeutics Corporation stock price growing?

UTHR is up 1.22% over the past week, up 12.12% over the past month and up 38.87% over the past year. The price is above its 200-day moving average of $532.84.

03What is United Therapeutics Corporation market cap?

United Therapeutics Corporation has a market capitalization of $26.07B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

04How volatile is UTHR stock?

In the latest trading session UTHR moved between $578.28 and $609.20, a range of 5.09% of its current price.

05What are UTHR stock 52-week high and low?

Over the past 52 weeks UTHR has traded between $432.53 and $609.99. The current price is at its 52-week high.

Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.